Quest Diagnostics Incorporated

Equities

DGX

US74834L1008

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 04:00:02 2024-05-28 pm EDT			5-day change	1st Jan Change
138.9 ^USD	-1.68%		-3.09%	+0.75%

May. 21	Declaration of Voting Results by Quest Diagnostics Incorporated	CI
May. 16	Quest Diagnostics Elects Robert B. Carte to Board of Directors	CI

Jim Davis to Assume as CEO of Quest Diagnostics Incorporated on November 1, 2022

October 20, 2022 at 06:45 am EDT

Quest Diagnostics Incorporated announced that Mr. Jim Davis will assume the responsibilities of CEO and President on November 1, 2022. Mr. Rusckowski will remain as Executive Chairman through March 2023.

Latest news about Quest Diagnostics Incorporated

Declaration of Voting Results by Quest Diagnostics Incorporated	May. 21	CI
Quest Diagnostics Elects Robert B. Carte to Board of Directors	May. 16	CI
Everlasting momentum	May. 16
Argus Research Adjusts Quest Diagnostics Price Target to $215 From $163	May. 16	MT
Baird Adjusts Price Target on Quest Diagnostics to $145 From $144, Keeps Neutral Rating	May. 16	MT
Argus Adjusts Price Target on Quest Diagnostics to $215 From $163, Keeps Buy Rating	May. 16	MT
ANALYST RECOMMENDATIONS : Ecolab, Texas Instruments, Cisco, Britvic, Shopify...	May. 16
Quest Diagnostics Keeps Quarterly Cash Dividend at $0.75 a Share, Payable on July 22 to Shareholders of Record on July 8	May. 15	MT
Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on July 22, 2024	May. 15	CI
Argus Raises Quest Diagnostics' Price Target to $163 From $155	May. 15	MT
Quest Diagnostics Appoints Murali Balakumar as Senior Vice President and Chief Information and Digital Officer	May. 06	CI
Quest Diagnostics to Acquire PathAI Diagnostics Assets in Collaboration Deal	May. 01	MT
Quest Diagnostics Forms Licensing Agreements with PathAI	May. 01	CI
Baird Adjusts Quest Diagnostics' Price Target to $144 From $138	Apr. 30	MT
US FDA publishes final rule for laboratory developed tests	Apr. 29	RE
Labcorp beats quarterly estimates on strong testing demand	Apr. 25	RE
Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155	Apr. 24	MT
UBS Adjusts Price Target on Quest Diagnostics to $146 From $139, Maintains Neutral Rating	Apr. 24	MT
Barclays Raises Quest Diagnostics' Price Target to $144 From $138	Apr. 24	MT
Deutsche Bank Adjusts Quest Diagnostics Price Target to $136 From $125, Maintains Hold Rating	Apr. 24	MT
Mizuho Adjusts Quest Diagnostics' Price Target to $155 From $150	Apr. 24	MT
Citigroup Adjusts Quest Diagnostics Price Target to $145 From $135	Apr. 24	MT
Leerink Partners Adjusts Quest Diagnostics Price Target to $141 From $135	Apr. 24	MT
Truist Raises Price Target on Quest Diagnostics to $150 From $145, Cites 'Strong Start' to 2024, Keeps Hold Rating	Apr. 24	MT
Evercore ISI Raises Quest Diagnostics Price Target to $145 from $140	Apr. 23	MT

Chart Quest Diagnostics Incorporated

Duration

Period

More charts

Company Profile

Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows: - testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services; - other (2.7%).

Sector

Healthcare Facilities & Services

Calendar

10:20am - Leerink Partners Healthcare Crossroads Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Quest Diagnostics Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

138.9 USD

Average target price

146.8 USD

Spread / Average Target

+5.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
QUEST DIAGNOSTICS INCORPORATED	+0.75%	15.7B
HCA HEALTHCARE, INC.	+17.73%	83.47B
CVS HEALTH CORPORATION	-32.08%	69.72B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-3.24%	26.37B
FRESENIUS SE & CO. KGAA	+4.13%	17.86B
LABCORP HOLDINGS INC.	-13.68%	16.83B
NATERA, INC.	+74.92%	13.45B
TENET HEALTHCARE CORPORATION	+73.16%	12.81B
REDE D'OR SÃO LUIZ S.A.	-2.02%	12.44B
FRESENIUS MEDICAL CARE AG	+3.58%	12.35B

Other Healthcare Facilities & Services